GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (FRA:8STN) » Definitions » Cyclically Adjusted PS Ratio

Sorrento Therapeutics (FRA:8STN) Cyclically Adjusted PS Ratio : (As of May. 23, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Sorrento Therapeutics Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sorrento Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sorrento Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Cyclically Adjusted PS Ratio Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.21 10.31 20.53 12.65 2.21

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.09 3.94 2.21 0.88 0.86

Competitive Comparison of Sorrento Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Sorrento Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sorrento Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's Cyclically Adjusted PS Ratio falls into.



Sorrento Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sorrento Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Sorrento Therapeutics's adjusted Revenue per Share data for the three months ended in Jun. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.03/128.7287*128.7287
=0.030

Current CPI (Jun. 2023) = 128.7287.

Sorrento Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201309 0.004 98.790 0.005
201312 0.004 98.326 0.005
201403 0.031 99.695 0.040
201406 0.022 100.560 0.028
201409 0.035 100.428 0.045
201412 0.022 99.070 0.029
201503 0.025 99.621 0.032
201506 0.029 100.684 0.037
201509 0.026 100.392 0.033
201512 0.032 99.792 0.041
201603 0.023 100.470 0.029
201606 0.017 101.688 0.022
201609 0.030 101.861 0.038
201612 0.065 101.863 0.082
201703 0.090 102.862 0.113
201706 0.059 103.349 0.073
201709 1.330 104.136 1.644
201712 0.207 104.011 0.256
201803 0.060 105.290 0.073
201806 0.033 106.317 0.040
201809 0.030 106.507 0.036
201812 0.050 105.998 0.061
201903 0.044 107.251 0.053
201906 0.043 108.070 0.051
201909 0.037 108.329 0.044
201912 0.071 108.420 0.084
202003 0.038 108.902 0.045
202006 0.037 108.767 0.044
202009 0.039 109.815 0.046
202012 0.035 109.897 0.041
202103 0.040 111.754 0.046
202106 0.039 114.631 0.044
202109 0.034 115.734 0.038
202112 0.037 117.630 0.040
202203 0.050 121.301 0.053
202206 0.027 125.017 0.028
202209 0.039 125.227 0.040
202212 0.031 125.222 0.032
202303 0.032 127.348 0.032
202306 0.030 128.729 0.030

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sorrento Therapeutics  (FRA:8STN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sorrento Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sorrento Therapeutics (FRA:8STN) Business Description

Traded in Other Exchanges
Address
4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (FRA:8STN) Headlines

No Headlines